| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
| 25 Apr 2023 | On business and financial situation | ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) | Download |
| 21 Feb 2023 | On business and financial situation | The Company releases the full year 2022 financial results presentation. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 13 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 October and 12 October 2023 | Download |
| 06 Oct 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 29 September and 5 October 2023 | Download |
| 02 Oct 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2023 | Download |
| 29 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 September and 28 September 2023 | Download |
| 22 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 September and 21 September 2023 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |